Dibenzo(a,e)fluoranthene (DBF), a highly carcinogenic polycyclic hydrocarbon without an apparent K-region, binds covalently to DNA, transfer RNA, and polyribonucleotides when incubated with hepatic microsomal fractions under standard conditions. Optimal binding conditions for [3H]DBF were established. Methylcholanthrene-pretreated mouse liver microsomes induced a higher level of binding of [3H]DBF to DNA than did similarly induced rat liver microsomes. 7,8-Benzoflavone strongly inhibited the binding of this polycyclic aromatic hydrocarbon to DNA, while cyclohexene oxide and trichloropropene oxide had an enhancing effect when used in the presence of rat liver microsomes. An unexpected inhibitory effect was observed with cyclohexene oxide in mouse liver microsome-enriched medium. [3H]DBF bound twice as much to denatured as to native DNA. Incubation of [3H]DBF in the presence of liver microsomes and polyribonucleotides (polyadenylate, polyuridylate, polyguanylate, and polyinosinate) indicated that binding occurs mainly with guanine. Binding of [3H]DBF to DNA of various origins was found to be directly proportional to the amount of GC pairs. Preliminary results indicate a covalent bond between DBF and nucleic acids.

Download full-text PDF

Source

Publication Analysis

Top Keywords

liver microsomes
16
carcinogenic polycyclic
8
polycyclic hydrocarbon
8
nucleic acids
8
mouse liver
8
binding [3h]dbf
8
[3h]dbf dna
8
rat liver
8
cyclohexene oxide
8
binding
6

Similar Publications

Novel tertiary diarylethylamines as functionally selective agonists of the kappa opioid receptor.

Bioorg Med Chem Lett

January 2025

Contineum Therapeutics, 3565 General Atomics Court, Suite 200, San Diego, CA 92121, United States.

Novel kappa opioid receptor (KOR) agonists that preferentially activate G-protein signaling versus β-arrestin-2 recruitment are described. Starting from a literature-reported phenol-containing diphenethylamine KOR agonist, structure-activity relationship (SAR) studies revealed replacement of the phenol with various non-hydroxylated bicyclic heteroaromatics led to tertiary diarylethylamines which retained KOR agonist activity and improved metabolic stability in human liver microsomes. Further optimizations produced compound 39, a potent activator of G-protein signaling (GTPγS EC = 14 nM, 83 % E) that did not elicit a β-arrestin-2 recruitment functional response (E < 10 %).

View Article and Find Full Text PDF

Cinnamon is one of the oldest known spices used in various food delicacies and herbal formulations. Cinnamaldehyde is a primary active constituent of cinnamon and substantially contributes to the food additive and medicinal properties of cinnamon. This report deals with cinnamaldehyde bioaccessibility, metabolic clearance, and interaction with human xenobiotic receptors (PXR and AhR).

View Article and Find Full Text PDF

Background: Givinostat, a potent histone deacetylase (HDAC) inhibitor, is promising for the treatment of relapsed leukemia and myeloma.

Purpose: This study aimed to develop and verify a quick assay for the measurement of givinostat concentration using ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) with eliglustat as the internal standard (IS), establishing a basic pharmacokinetic profile for its pre-clinical application and metabolic stability in vitro.

Methods: Sample preparation was performed via protein precipitation using acetonitrile.

View Article and Find Full Text PDF

Design, synthesis, and antitumor evaluation of triazolopyridine derivatives as novel inhibitors for BRD4.

Eur J Med Chem

January 2025

Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, PR China. Electronic address:

The bromodomain-containing protein 4 (BRD4) is an epigenetic regulatory 'reader' belonging to the bromodomain and extra-terminal domain (BET) family. Several studies have demonstrated that the high expression of BRD4 is closely related to the occurrence and development of various cancers, so BRD4 has become a promising target for cancer treatment. However, there are no drugs targeting BRD4 available on the market, the development of novel BRD4 inhibitors is of great significance.

View Article and Find Full Text PDF

Structure-based discovery of novel diarylpyrimidines as potent and selective Non-Nucleoside reverse transcriptase inhibitors: From CH(CN)-Biphenyl-Diarylpyrimidines to CNNH-Biphenyl-Diarylpyrimidines.

Eur J Med Chem

January 2025

Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China; Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, 200433, China; Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai, 200433, China; Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang, 330022, China. Electronic address:

In order to enhance the anti-HIV-1 potency and selectivity of the previously reported compound 3 (EC = 27 nM, SI = 1361), a series of novel biphenyl-diarylpyrimidine derivatives were developed by employing structure-based drug design strategy. Among these derivatives, compound M44 demonstrated the most potent inhibitory activity against wild-type (WT) HIV-1 as well as five drug-resistant mutants (EC = 5-148 nM), which were 5-173 times more potent than that of 3 (EC = 27-9810 nM). Furthermore, this analogue exhibited approximately 11-fold lower cytotoxicity (CC = 54 μM) than that of etravirine and rilpivirine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!